Immunic, Inc. (IMUX)
8.19
+0.63
(+8.33%)
USD |
NASDAQ |
Oct 09, 16:00
8.13
-0.06
(-0.73%)
After-Hours: 20:00
Immunic Cash from Operations (Quarterly) : -31.00M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -31.00M |
| March 31, 2026 | -17.30M |
| December 31, 2025 | -19.28M |
| September 30, 2025 | -20.14M |
| June 30, 2025 | -24.61M |
| March 31, 2025 | -21.78M |
| December 31, 2024 | -22.96M |
| September 30, 2024 | -20.80M |
| June 30, 2024 | -17.03M |
| March 31, 2024 | -23.97M |
| December 31, 2023 | -14.03M |
| September 30, 2023 | -17.31M |
| June 30, 2023 | -19.98M |
| March 31, 2023 | -19.51M |
| December 31, 2022 | -15.10M |
| September 30, 2022 | -13.60M |
| June 30, 2022 | -15.76M |
| March 31, 2022 | -20.68M |
| December 31, 2021 | -23.68M |
| September 30, 2021 | -17.60M |
| June 30, 2021 | -29.00M |
| March 31, 2021 | -12.95M |
| December 31, 2020 | -13.96M |
| September 30, 2020 | -11.90M |
| June 30, 2020 | -9.227M |
| Date | Value |
|---|---|
| March 31, 2020 | -11.03M |
| December 31, 2019 | -6.535M |
| September 30, 2019 | -5.976M |
| June 30, 2019 | -10.99M |
| March 31, 2019 | -5.317M |
| December 31, 2018 | -3.445M |
| September 30, 2018 | -2.085M |
| June 30, 2018 | 8.866M |
| March 31, 2018 | -13.07M |
| December 31, 2017 | -9.92M |
| September 30, 2017 | -9.417M |
| June 30, 2017 | -10.15M |
| March 31, 2017 | -10.91M |
| December 31, 2016 | -9.102M |
| September 30, 2016 | -7.889M |
| June 30, 2016 | -8.827M |
| March 31, 2016 | -9.956M |
| December 31, 2015 | -9.291M |
| September 30, 2015 | -12.04M |
| June 30, 2015 | -15.12M |
| March 31, 2015 | -13.51M |
| December 31, 2014 | -10.39M |
| September 30, 2014 | -11.19M |
| June 30, 2014 | -9.878M |
| March 31, 2014 | -9.364M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Sionna Therapeutics, Inc. | -22.22M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Anika Therapeutics, Inc. | -0.684M |
| Savara, Inc. | -29.75M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.249M |
| Cash from Financing (Quarterly) | 0.118M |
| Free Cash Flow | -88.05M |
| Free Cash Flow Per Share (Quarterly) | -0.735 |
| Free Cash Flow to Equity (Quarterly) | -31.39M |
| Free Cash Flow to Firm (Quarterly) | -31.25M |
| Free Cash Flow Yield | -41.32% |